AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Investing.com - AbbVie (NYSE: ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol-Myers Squibb Company PFD CONV 2 (OTCPK:BMYMP) had declared $0.50/share quarterly dividend Payable Dec. 2; for shareholders of record Nov. 5; ex-div Nov. 5. See BMYMP Dividend Scorecard, Yield ...

In September, the FDA approved the drug previously known as KarXT as a novel antipsychotic therapy for adults with schizophrenia. Citing new topline data from its 52-week open-label studies ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to IQVIA RDS (India) for conducting the trial of KarXT, a ...